Herpetic Keratitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Herpetic Keratitis – Drugs In Development, 2024 report and make more profitable business decisions.
Herpetic Keratitis is an inflammation or infection of cornea of the eye caused by HSV (herpes simplex virus). It is a viral infection and is classified as type-1 and type-2. Spread of HSV to the eyes causes herpetic keratitis. Presence of HSV infection and other triggering factors like exposure to direct sunlight, drug-induced, stress. Herpetic keratitis is further classified as epithelial keratitis, immune stromal keratitis, stromal necrotic, and endothelium. Conjunctivitis or red eyes is the common symptom that causes blurred vision, watery eyes, redness, sting, and irritation. Stopping the spread of infection is the preventive measure to be taken and topical anti-viral medications and steroids to treat pain and discomfort. Corneal transplant in complicated or severe cases is recommended.
The Herpetic Keratitis drugs in development market research report provide comprehensive information on the therapeutics under development for Herpetic Keratitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpetic Keratitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Herpetic Keratitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Herpetic Keratitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Herpetic Keratitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Herpetic Keratitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Cumulus Pharmaceutical LLCEditas Medicine Inc
Fox Chase Chemical Diversity Center Inc
Marinomed Biotech AG
NanoViricides Inc
Shulov Innovative Science Ltd
Trefoil Therapeutics LLC
Viraze
Zhejiang Raytone Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Herpetic Keratitis reports